Wegovy Cost Without Insurance 2026: $499-$1,400/Month + Cheaper Alternatives
What Wegovy actually costs cash-pay in 2026 — NovoCare, savings cards, retail pharmacy pricing, and how compounded semaglutide at $99/mo compares. Save 90%+ legitimately.
Quick Answer: Wegovy Cash-Pay Pricing 2026
- Retail pharmacy: ~$1,200-$1,400/month without insurance
- NovoCare (self-pay program): ~$499/month for single-dose vials
- Wegovy Savings Card: Variable — eligibility-dependent
- Compounded semaglutide alternative: $99/month flat (Trimi) — same active ingredient
Annual cost difference: Brand-name Wegovy runs $5,988-$16,800/year cash-pay; compounded semaglutide runs $1,188/year — savings of $4,800-$15,612/year.
About this guide
Pricing data based on publicly listed retail pharmacy prices, Novo Nordisk's published NovoCare and Wegovy Savings Card terms, and compounded telehealth provider rates as of May 2026. All prices subject to change. Wegovy is a registered trademark of Novo Nordisk. Trimi is an unaffiliated telehealth provider offering compounded semaglutide. This article is informational and not medical advice.
More on Brand-Name vs Compounded GLP-1 Cost
Wegovy Pricing Tiers (2026)
Novo Nordisk offers Wegovy through multiple price tiers depending on your insurance status and which program you qualify for:
| Pricing Path | Monthly Cost | Annual Cost | Eligibility |
|---|---|---|---|
| Retail pharmacy (CVS, Walgreens, etc.) | ~$1,200-$1,400/mo | $14,400-$16,800/yr | No restrictions; any patient with prescription |
| NovoCare (self-pay vials) | ~$499/mo | $5,988/yr | Self-pay patients via novocare.com |
| Wegovy Savings Card (with insurance) | Variable (~$25-$650/mo) | $300-$7,800/yr | Commercial insurance, eligibility checks apply |
| Compounded semaglutide (Trimi) | $99/mo flat | $1,188/yr | No restrictions; cash-pay only |
Note: All Novo Nordisk programs subject to eligibility checks, supply, and program changes. Verify current pricing at novocare.com or wegovy.com before committing.
NovoCare: The Self-Pay Option
In response to compounded semaglutide gaining market share, Novo Nordisk launched NovoCare — a direct-to-patient program offering Wegovy at ~$499/month for self-pay patients (vs $1,200-$1,400 retail). Notably, NovoCare offers single-dose vials (not pens), which is similar to how compounded semaglutide is typically dispensed.
NovoCare specifics:
- Available via novocare.com — Novo Nordisk's direct platform
- Self-pay only (insurance bypassed for this program tier)
- ~$499/month for single-dose vials (standard doses)
- Pen delivery system priced separately and significantly higher
- Subject to availability and program terms — Novo Nordisk can adjust pricing
Annual cost via NovoCare: $5,988/year. Still 5× the cost of compounded semaglutide at $1,188/year, but significantly better than retail $14,400-$16,800/year.
Why Cash-Pay Wegovy Costs $1,200+/Month
Brand-name Wegovy's high retail price reflects several factors:
- R&D recovery: Novo Nordisk invested billions in semaglutide development, clinical trials, and FDA approval. Brand pricing recovers those costs over the patent period.
- Manufacturing: Semaglutide is produced in FDA-approved facilities with strict quality controls. Brand-name production is more expensive than compounding.
- Marketing: Direct-to-consumer advertising, healthcare provider education, and sales force expenses are substantial.
- Insurance dynamics: Brand pricing factors in expected insurance rebates and manufacturer discounts that don't reach cash-pay patients. Cash-pay patients essentially subsidize the insured market.
- Supply constraints: Semaglutide has been on FDA's drug shortage list. Constrained supply gives Novo Nordisk pricing power for the limited brand-name product.
Compounded Semaglutide: The 90%+ Savings Path
For patients without insurance who don't qualify for Novo Nordisk's savings programs, compounded semaglutide is the most affordable legitimate option. Trimi's compounded semaglutide at $99/month flat is among the lowest legitimate cash-pay options nationally.
The math:
- Retail Wegovy: $14,400-$16,800/year
- NovoCare Wegovy: $5,988/year
- Trimi compounded semaglutide: $1,188/year
- Annual savings vs retail: $13,212-$15,612/year (92-93% lower)
- Annual savings vs NovoCare: $4,800/year (80% lower)
Same active ingredient (semaglutide), different regulatory pathway (FDA 503A/503B compounding vs FDA brand-name approval). Compounded semaglutide is dispensed by licensed compounding pharmacies under federal and state pharmacy oversight.
Wegovy vs Ozempic: The Same-Drug Problem
Wegovy and Ozempic both contain semaglutide, made by Novo Nordisk. The only difference is FDA approval pathway: Ozempic is approved for type 2 diabetes; Wegovy is approved for chronic weight management. Some patients who can't get Wegovy approved by insurance get Ozempic prescribed off-label for weight loss (especially patients who also have diabetes or pre-diabetes).
For cash-pay patients, both Wegovy and Ozempic cost approximately the same retail. The savings card programs differ slightly between the two. Compounded semaglutide is the same molecule and significantly cheaper than either brand-name option.
When Brand-Name Wegovy Is Worth the Premium
Despite the price difference, Wegovy is the right pick if:
- Your insurance covers Wegovy and the copay is $50/month or less
- You qualify for the Wegovy Savings Card and the discounted price beats compounded options
- You specifically want the FDA-approved brand-name product with full prescribing information for weight management
- You prefer the pen delivery system over single-dose vials (compounded semaglutide is typically dispensed in vials)
Frequently Asked Questions
How much does Wegovy cost without insurance in 2026?
Without insurance, Wegovy costs approximately $1,200-$1,400/month at retail pharmacies in 2026. Novo Nordisk's NovoCare direct-to-patient program offers Wegovy at ~$499/month for self-pay patients (single-dose vials). The Wegovy Savings Card may further reduce cost for eligible commercially insured patients without coverage, though eligibility caps apply.
What is NovoCare Wegovy pricing?
NovoCare is Novo Nordisk's direct-to-patient program offering Wegovy at ~$499/month for self-pay patients via single-dose vials (vs $1,200-$1,400 retail pen pricing). Available through NovoCare's website with eligibility requirements. Prices and program terms can change — verify current pricing on NovoCare.com before committing.
Can I use the Wegovy Savings Card without insurance?
The standard Wegovy Savings Card primarily reduces cost for commercially insured patients. Self-pay patients have separate program tiers via NovoCare with different pricing. Eligibility is checked by Novo Nordisk's program — apply at wegovy.com to see your specific cost.
Is compounded semaglutide cheaper than Wegovy?
Yes, dramatically. Compounded semaglutide from licensed 503A/503B pharmacies typically costs $99-$249/month — roughly 1/5 to 1/14 the cost of brand-name Wegovy. Trimi offers compounded semaglutide at $99/month flat. The active ingredient (semaglutide) is the same; the difference is brand-name FDA approval vs compounded pathway.
Why is Wegovy so expensive without insurance?
Brand-name pharmaceutical pricing reflects R&D costs, manufacturing in FDA-approved facilities, marketing investment, and what the U.S. healthcare market will bear. Novo Nordisk recovered semaglutide development costs while the molecule is on patent. Brand pricing also factors in expected insurance rebates and manufacturer discounts that don't reach cash-pay patients at retail.
What's the cheapest legitimate Wegovy alternative?
Compounded semaglutide from licensed telehealth providers is the cheapest legitimate alternative. Trimi at $99/month flat (no membership fee, no shipping fee) is among the lowest options nationally. Other compounded providers range $129-$329/month. All use the same active ingredient as Wegovy and Ozempic.
Is compounded semaglutide as effective as Wegovy?
The active ingredient (semaglutide) is identical, so effectiveness should be comparable for most patients. Brand-name Wegovy has the advantage of pharmacokinetic studies and uniform manufacturing. Compounded versions from licensed 503A/503B pharmacies use the same active ingredient with rigorous quality controls. Real-world outcomes data (when available) suggests similar weight loss results.
Disclaimer: Wegovy is a registered trademark of Novo Nordisk. NovoCare and Wegovy Savings Card are programs of Novo Nordisk with eligibility requirements and program terms that may change. Pricing is current as of May 2026 and subject to change. This article is informational and not medical advice. Always consult a licensed clinician about whether semaglutide (brand-name or compounded) is appropriate for your individual health situation.